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Abstract
We examined recurrent Buruli ulcer cases following treatment and assumed cure in a large
cohort of Australian patients living in an endemic area. We report that while the recurrence
rate was low (2.81 cases/year/1000 population), it remained similar to the estimated risk of
primary infection within the general population of the endemic area (0.85–4.04 cases/year/
1,000 population). The majority of recurrent lesions occurred in different regions of the body
and were separated by a median time interval of 44 months. Clinical, treatment and epidemi-
ological factors combined with whole genome sequencing of primary and recurrent isolates
suggests that in most recurrent cases a re-infection was more likely as opposed to a relapse
of the initial infection. Additionally, all cases occurring more than 12 months after com-
mencement of treatment were likely re-infections. Our study provides important prognostic
information for patients and their health care providers concerning the nature and risks
associated with recurrent cases of Buruli ulcer in Australia.
Author summary
Mycobacterium ulcerans (M. ulcerans) causes a necrotising infection of skin and soft-tissue
known as Buruli ulcer. Since the regular use of antibiotics for Buruli ulcer treatment in
Australian populations was introduced at the turn of the century, treatment success rates
have been very high. However there is no information from the Australian setting on the
risk of recurrent disease following treatment and assumed cure, despite this being impor-
tant prognostic information for patients, their families and health-care providers. Further-
more, it is also not known if recurrent disease represents late relapse of the initial treated
infection or a subsequent new infection. In our study we have shown for the first time in
Australian patients living in an endemic area that the incidence of recurrent Buruli ulcer
following treatment and healing is low, and that this risk is similar to the estimated risk of
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primary infection within the general population of the endemic area. Furthermore, we
have used clinical, treatment and epidemiological data supported by genomic information
of M. ulcerans organisms to determine that the majority of recurrent lesions appear to
result from re-infection. This suggests that for a proportion of treated patients’ acquired
protective immunity against the development of recurrent M. ulcerans disease does not
develop from their initial infection.
Introduction
Mycobacterium ulcerans (M. ulcerans) causes a necrotising infection of skin and soft-tissue
known as Buruli ulcer.[1] Since the regular use of antibiotics for Buruli ulcer treatment in Aus-
tralian populations was introduced at the turn of the century, treatment success rates have
been very high.[2–4] Disease cure has assumed to occur if lesions have healed and there have
been no recurrent lesions within 12 months of commencing treatment.[1,5] However, disease
recurrence is known to occur.[6] At present there is no information from the Australian set-
ting on the risk of recurrent disease following treatment and assumed cure, despite this being
important prognostic information for patients, their families and health-care providers. Fur-
thermore, it is also not known if recurrent disease represents a late relapse of the initial treated
infection or a subsequent re-infection. Clarifying this issue may shed some light on the effec-
tiveness of current treatments if recurrent lesions represent late disease relapse. On the other
hand, if they represent re-infection, this may shed some light on the effectiveness of an individ-
ual’s immunity against new infections following eradication of an initial M. ulcerans infection,
as well as ongoing transmission risk in the community. For the first time, whole genome
sequencing has recently been used to examine this issue in four cases of recurrent M. ulcerans
disease in Benin, Africa, and suggested that three of the cases represented disease relapse and
one re-infection.[6]
The aim of our study was to determine the risk of recurrent M. ulcerans lesions following
treatment and assumed cure in an Australian population and to use whole genome sequencing
techniques combined with clinical, treatment and epidemiological data to determine whether
recurrent lesions represented late disease relapse or re-infection.
Methods
All confirmed M. ulcerans cases managed at Barwon Health, a tertiary referral institution in
Victoria, Australia, from 1/1/1998-31/12/2016 were included in the study. A M. ulcerans case
was defined as the presence of a lesion clinically suggestive of M. ulcerans plus any of (1) a cul-
ture of M. ulcerans from the lesion, (2) a positive PCR from a swab or biopsy of the lesion, or
(3) histopathology of an excised lesion showing a necrotic granulomatous ulcer with the pres-
ence of acid-fast bacilli (AFB) consistent with acute M. ulcerans infection.
Recurrence was defined as a new M. ulcerans lesion appearing after the original lesion had
healed that was culture positive for M. ulcerans and occurred 12 months after initial treat-
ment. Patients were not actively followed up after 12 months from treatment commencement,
therefore diagnosis of recurrence relied upon self-presentation or referral to our health service.
A ‘significant risk’ of relapse following initial treatment was defined as a) those who had
surgery without at least 2 weeks of known effective combination antibiotics based on our pub-
lished risk of relapse of 32% in those who have had surgery alone,[7] and our published treat-
ment success rates in those who have surgery combined with at least 14 days of antibiotics)[8],
Recurrent Buruli ulcer in treated Australian patients
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006724 August 13, 2018 2 / 10
or b) those who had antibiotics alone but did not complete the recommended 56 days duration
of known effective combination antibiotics.[9]
Where available, whole genome sequencing and single nucleotide polymorphism (SNP)
analysis was performed to examine genetic relationships between pairs of isolates from the
same patient (two patients did not have paired isolates available). A total of 10 isolates, derived
from five patients with recurrent disease, were subjected to whole genome sequencing
(Table 1). Whole genome sequencing was performed as previously described.[10] Reads were
then mapped against the M. ulcerans Agy99 genome [11], including the pMUM001 plasmid
[12] and core SNPs across the 10 isolates identified using Samtools. Whole genome SNP analy-
sis was also performed on an additional six previously sequenced M. ulcerans isolates obtained
from the same endemic region (Bellarine Peninsula) [13].
Data was collected prospectively using Epi-info 6 (CDC, Atlanta, GA, USA) and analysed
using STATA 12 (StataCorp, College Staton, TX, USA).
Ethics
This study was approved by the Barwon Health Human Research and Ethics Committee. All
previously gathered human medical data were analysed in a de-identified fashion.
Results
A total of 426 patients with M. ulcerans were managed at Barwon Health during the study
period and included in the analysis. The median age was 57 years (IQR 37–73 years) and 225
(52.8%) were male. Thirty-four (8.0%) patients had diabetes and 35 (8.2%) were immune sup-
pressed. Lesions were classified as World Health Organization (WHO) category one for 79.3%,
category two for 10.6% and category three for 10.1% of lesions. The clinical type of lesion was
classified as an ulcer for 85.1%, nodule for 6.1%, oedematous for 7.8% and plaque for 0.9%.
The median duration of symptoms prior to diagnosis was 42 days (IQR 28–75 days).
Of this cohort, seven (1.6%) patients were diagnosed with a recurrent lesion (Table 1). This
was over a combined follow-up time since commencement of treatment until the time of study
analysis (12/4/18) of 2813 years, with a median follow-up time of 5.7 years (IQR 3.3–9.4 years).
The rate of a recurrent lesion was 2.81 per 1000 person years (95% CI 1.19–5.22 per 1000 per-
son years) (Fig 1). There were no significant differences in the baseline characteristics between
those with a recurrence and those without a recurrence. (Table 2)
The recurrent lesions occurred a median 44 months (IQR 16–68 months) after treatment
commenced for the initial lesion; 5/7 recurrences occurred at least 3.4 years from the initial
lesion. Four (57%) recurrences were on a completely separate limb and side of the body, one
was on the same limb but different region of that limb and 2 were on the same limb and in the
same region.
Treatment of the initial lesion involved surgery alone for 1 patient, antibiotics alone for 2
patients, and antibiotics combined with surgery for 4 patients (Table 1). According to the ini-
tial treatment, 3/7 (43%) patients were assessed as having a ‘significant risk’ of relapse; patient
#1 had only 37 days of combined antibiotics alone, patient #4 had excision combined with
antibiotic monotherapy with clarithromycin, and patient #6 had excision alone without
adjunctive antibiotics and had positive surgical margins.
Whole genome pairwise comparisons of the paired isolates revealed close genetic similarity
between pairs (Fig 2). Indeed, based on our SNP analysis the paired isolates from the patients
#3 (mu77/mu489) and #2 (mu327/mu432) were genetically identical (Fig 2, Table 3). In con-
trast, paired isolates from patients #1, #4 and #5, contained SNP differences between each pair
(Fig 2, Table 3). To put this genetic variation in context, we also performed SNP analysis on an
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additional six unrelated human M. ulcerans isolates from the same endemic area. Three of the
six isolates (mu74, muJKD8049, mu08009899) were genetically identical to each other follow-
ing SNP analysis (Fig 2). Three isolates (mu146, mu_UK35 and mu487) from the paired cases
Table 1. Patient characteristics associated with paired isolates from initial and recurrent episodes of M. ulcerans disease in Barwon Health Cohort 1998–2016.
Pair
number
Isolate Date of
diagnosis
Time
between
diagnosis of
lesions
(months)
Age at
diagnosis
(years)
Gender Site of
lesion
Type of
lesion
WHO
category
Treatment Significant risk
of relapse
following
treatment of
initial lesion
Proposed
re-infection
or relapse
1 mu614 5/12/11 44 55 M Left leg Ulcer x 2 3 R + Cp 37D Yes Re-
infectionmu_UK35 17/8/15 58 Left leg Oedema 2 R + Cla 84D.
Surgical
debridement D91
atbs (cultures
overgrown)
2 mu327 06/12/
2011
12 24 M Right leg Ulcer 1 Rif + Cp 56D No Relapse
mu432 27/11/
2012
25 Right leg Ulcer 1 Nil
3 mu77 29/9/2004 46 87 F Right
forearm
ulcer 1 R + Cp for 90D.
Excision and
primary closure
D10 atbs (Positive
margins, culture not
done).
No Re-
infection
with same
genotype
mu489 17/7/2008 91 Left ankle ulcer x 2 3 Cp + Cla for 85D.
Excision + SSG D4
atbs. (Culture
positive)
4 mu146 22/6/06 72 44 M Left arm ulcer 1 Cla for D40.
Excision + closure
D9 atbs. (margins
negative, culture not
done)
Yes Re-
infection
mu403 6/7/12 50 Left elbow ulcer 1 R + Cla for 56D.
5 mu382 21/5/12 16 75 M Left wrist
+ forearm
Oedematous 3 R + Cp for 100D.
Debridement D25
atbs (Margins
positive but culture
negative).
No Re-
infection
mu487 30/9/13 77 R lower
leg
ulcer 1 R + Cla for 56D.
Debridement D56
(margins Positive,
culture negative)
6 Not
available
10/10/05 41 86 F Right
buttock
Ulcer 1 Excision + closure.
Surgical margins
positive.
Yes Re-
infection
Not
available
3/4/09 89 Left leg Ulcer 1 Excision + closure.
R + Cp for 28D.
7 Not
available
20/10/05 68 36 M Right leg Ulcer 1 R + Cla for 14D.
Excision + closure
D4 atbs (Margins
negative, culture not
done).
No Re-
infection
Not
available
4/7/11 42 Left knee Ulcer 1 R + Cp for 56D.
M: male, F: female, R: rifampicin, Cp: ciprofloxacin, Cla: clarithromycin, D: days, atbs: antibiotics, SSG: split skin graft
https://doi.org/10.1371/journal.pntd.0006724.t001
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were also genetically identical to these isolates demonstrating that even apparently unrelated
isolates can share a common genotype. Furthermore, this genotype appeared the most domi-
nant within the Bellarine Peninsula isolates we examined. Within two of the three pairs that
contained this ‘common’ genotype (#1 and 5), the primary isolate was more genetically
Fig 1. Cumulative proportion of patients with recurrent M. ulcerans lesions in the Barwon Health cohort 1998–2016.
https://doi.org/10.1371/journal.pntd.0006724.g001
Table 2. Comparison of patient characteristics at diagnosis of initial M. ulcerans lesion stratified by the occur-
rence of a recurrent lesion.
Variable Recurrence No Recurrence p-value
Gender
Male 5 220 0.32
Female 2 199
Median Age (years;IQR) 55 (36–86) 57 (37–73) 0.61
Diabetes 1 33 0.49
Immune suppressed 1 34 0.56
WHO category
One 5 318 0.20
Two 0 43
Three 2 39
Lesion Type
Ulcer 6 355 0.83
Nodule 0 26
Oedema 1 32
Plaque 0 4
Median duration of symptoms prior to diagnosis (days;IQR) 36 (21–56) 42 (28–75) 0.43
https://doi.org/10.1371/journal.pntd.0006724.t002
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divergent from this ‘common’ genotype compared to the second (reoccurring) isolate. The
time interval between recurrent lesions did appear to greatly influence the number of SNP dif-
ferences between the isolates.
Fig 2. Median joining network of 10 M. ulcerans isolates derived from five recurrent cases of M. ulceransdisease in south-eastern Victoria. Node colours represent
paired isolates, grey nodes represent six unrelated isolates also from M. ulcerans. The size of each node is proportional to the number of isolates with identical genotypes.
Edges are labelled with the number of SNPs between each node. Asterisks show the primary (or initial) isolate.
https://doi.org/10.1371/journal.pntd.0006724.g002
Table 3. Genetic changes between paired isolates. ‘Position’ references to the reference genome Agy99 (NC_008611).
Pair
number
Isolates No.
SNPs
Position and nucleotide change Gene (amino acid change) Proposed re-infection or
relapse
1 mu614 vs.
mu_UK35
2 5258932 (AT) unique insert in mu614 intergenic Re-infection
2 mu327 vs. mu432 0 Relapse
3 mu77 vs. mu489 0 Re-infection with same
genotype
4 mu146 vs. mu403 2 4590438 (G/C) unique to mu403 328887 (T/G) unique
to mu403
FdxB (Gly/Ala)
Acyl-CoA dehydrogenases (Lys/
Thr)
Re-infection
5 mu382 vs. mu487 1 5352860 (A/G) unique to mu382 FadD12_2 (Cys/Arg) Re-infection
https://doi.org/10.1371/journal.pntd.0006724.t003
Recurrent Buruli ulcer in treated Australian patients
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006724 August 13, 2018 6 / 10
Discussion
Our study has shown that Buruli ulcer has a low recurrence rate in treated Australian patients
with an assumed cure living in an endemic region. This provides important prognostic infor-
mation for patients and their health providers, and may help alleviate the often substantial fears
that patients have of becoming reinfected once their initial lesion has been cured. Although the
low risk is reassuring, the fact that it can occur means that patients and clinical staff need to be
educated and aware of this possibility, so that any recurrent lesions are assessed and diagnosed
early when lesions are small, enabling less complex treatment with better outcomes [5]. It is also
important to recognise that recurrent lesions can occur many years later and commonly occur
on completely different regions of the body compared to the initial lesion. In our study we did
not detect an increased risk of recurrent lesions associated with patient characteristics which
included age, gender, WHO category and type of lesion, diabetes, immune suppression and the
duration of symptoms prior to diagnosis. Although we did not examine host genetics, previous
studies have identified genetic factors associated with increased susceptibility to M. ulcerans
that may influence the risk of recurrent disease. [14,15] We would suggest future studies be per-
formed to assess whether host genetics can predict those at risk of recurrences, or whether this
is more likely determined by the intensity of re-exposure.
The whole genome sequence analysis revealed a mix of genetic relationships between iso-
lates. Paired isolates from some patients (#2 and #3) were genetically identical, possibly sug-
gesting either late relapse of the initial infection or re-infection from a genetically homogenous
source. In the case of patient #3, the extended time between recurrence (46 months), the fact
that the patient received highly effective treatment, and the fact that the lesions were identified
in different body areas (right forearm and left ankle), suggests that re-infection from a geneti-
cally homogenous source was more likely. While it’s hard to estimate the degree of genetic
change that would occur during a latency period in vivo, we assume that some mutations
would occur with longer periods (particularly 46 months). In contrast, the isolates from patient
#2 –also genetically identical–were only separated by 12 months, and occurred on the same
body region. In this case, a late relapse of the initial infection would appear more likely.
There were genetic differences between three of the paired isolates (patients #1, #4, and #5)
which can be interpreted in two ways. Firstly, it’s possible that they are the result of re-infec-
tion from a genetically heterogeneous population. In support of this hypothesis, our previous
research examining family clusters of M. ulcerans cases in Australia suggests that exposure risk
to M. ulcerans is short-term and may not necessarily be from a genetically homogeneous
source [10]. However, given that M. ulcerans is highly clonal in Australia, with only minor
genetic variation [13,16], it is expected that some re-infection cases will also be from geneti-
cally identical sources. The case of patient #3, discussed above, would be an example here. The
second possible explanation is that the bacterium genetically evolves during its latency period
in vivo and thus the cases represent late disease relapse despite a small number of SNP differ-
ences. In the case of patients #1 and #5 this latter hypothesis cannot be ruled out, but seems
unlikely as in both cases the primary (first) isolate had genetically diverged more from the
‘common’ dominant genotype compared to the second isolate. This is further supported in
patient #1 by the long duration between lesions (44 months) and in patient #5 by the recurrent
lesion being situated on a completely different body area and the initial treatment being highly
effective for curing BU. Combined, these findings suggests that re-infection with a different
genotype was the most plausible explanation for the #1 and #5 cases.
In comparison with the other known study by Eddyani et al. from Africa [6] that looked at
recurrent BU cases post treatment between 1989 and 2010 using whole genome sequencing,
their recurrence rate (100/4951 cases; 2.0%) was similar to ours (1.6%). However this study
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included recurrent lesions occurring from 6 months following treatment meaning their
recurrence rate according to our definition ( 12 months) would have been lower. With in-
formation from clinical, treatment and epidemiological data supported by whole genome
sequencing, 80% of our cases were classified as re-infection whereas 75% of their cases were
classified as relapse. In the African study, none of the three cases classified as relapse received
effective antibiotics against M. ulcerans, putting them at higher risk of relapse [7], and in 2 of
the three cases the isolates were genetically identical. The third relapse isolate differed by only
1 SNP and occurred on the same body region within a short time interval (9.5 months). In
their single case classified as re-infection, the second lesion was on a separate body area and
the isolate had a 20 SNP difference compared to the original one. Thus their interpretations
were similar to ours whereby the one case we classified as relapse (#2) had a genetically identi-
cal isolate on the same region of the body within a short time interval (12 months), whereas
those classified as re-infection had a combination of either being genetically distinct isolates
(#1,4,5), on separate body areas (#3,4,5), having had highly effective treatment (#3 and 5) or
having a long time interval between cases (#1,3,4). From both studies it is evident that whole
genome sequencing can be a useful tool in helping to clarify the likelihood of BU relapse versus
re-infection post treatment, as has been the case with tuberculosis [17].
The two recurrent cases who did not have paired isolates available for WGS (#6 and 7) were
classified as re-infections based on a combination of separate body areas (#6 and 7), highly
effective treatment (#7) and having a long time interval between cases (#6 and 7). Additionally,
our data suggesting that all recurrent cases which occurred more than 12 months after treat-
ment commenced were classified as re-infections, and the only one occurring after 12 months
was classified as disease relapse, would support our previous clinical definitions that treatment
failure occurs when a recurrent lesion appears within 12 months of commencing treatment[5].
If, as suggested by our study, most recurrent cases result from re-infection, then at least for a
proportion of treated patients acquired protective immunity against the development of recurrent
M. ulcerans disease does not develop following an initial infection. Interestingly, the rate of recur-
rence (2.81 cases/year/1000 population) was similar to the estimated risk of infection in the general
population of the Bellarine Peninsula (0.85–4.04 cases/year/1,000 population)[18], suggesting that
there may be no significant risk reduction against future infection for previously treated patients.
This is in contrast to a study from Uganda in the 1970s which suggested an 88% protective effect
over 4 years against recurrent M. ulcerans disease in those with a prior history of the disease.[19]
A limitation of our study is that we relied on self-presentation or referral to our health ser-
vice for diagnosis of recurrent lesions more than 12 months after treatment commenced and
therefore there is a risk that some recurrent lesions were not captured in our study. However,
as we are the only specialised health service in our region managing M. ulcerans it is likely that
any recurrent lesions in patients would have be managed at Barwon Health and therefore we
feel the risk of missing recurrent lesions would be small. Additionally, as the incidence of M.
ulcerans in the Bellarine Peninsula has fallen in recent years,[20] if this reduction relates to
reduced environmental pressure for infection we may have underestimated the risk of recur-
rent lesions that would occur if the pressure had remained constant. It is also recognised that
the number of recurrent cases where isolates had WGS performed was small meaning our
results need to be interpreted with some caution. Further research involving WGS of more iso-
lates from recurrent cases should be performed to further validate these findings.
Conclusions
There is a low incidence of recurrent Buruli ulcer in treated Australian patients living in
endemic regions and the risk is similar to the estimated risk of primary infection within the
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general population of the endemic area. The majority of recurrent lesions appear to result
from re-infection suggesting that for a proportion of treated patients lifelong immunity against
M. ulcerans re-infection does not develop.
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